| [1] |
Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol, 2021, 19(1): 55-71.
doi: 10.1038/s41579-020-0433-9
|
| [2] |
Krautkramer KA, Fan J, Backhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol, 2021, 19(2): 77-94.
doi: 10.1038/s41579-020-0438-4
|
| [3] |
Cani PD. Microbiota and metabolites in metabolic diseases. Nat Rev Endocrinol, 2019, 15 (2): 69-70.
doi: 10.1038/s41574-018-0143-9
pmid: 30602737
|
| [4] |
Agus A, Clement K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut, 2021, 70(6): 1174-1182.
doi: 10.1136/gutjnl-2020-323071
pmid: 33272977
|
| [5] |
Wang K, Zhang ZW, Hang J, Liu J, Guo FS, Ding Y, Li M, Nie QX, Lin J, Zhuo YY, Sun LL, Luo X, Zhong QH, Ye C, Yun CY, Zhang Y, Wang J, Bao R, Pang YL, Wang G, Gonzalez FJ, Lei XG, Qiao J, Jiang CT. Microbial- host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science, 2023, 381(6657): eadd5787.
doi: 10.1126/science.add5787
|
| [6] |
Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev, 2014, 35(6): 992-1019.
doi: 10.1210/er.2014-1035
pmid: 25216328
|
| [7] |
Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, Braverman S, Tengeler AC, Barak O, Elazar M, Ben-Zeev R, Lehavi-Regev D, Katz MN, Pevsner-Fischer M, Gertler A, Halpern Z, Harmelin A, Aamar S, Serradas P, Grosfeld A, Shapiro H, Geiger B, Elinav E. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science, 2018, 359(6382): 1376-1383.
doi: 10.1126/science.aar3318
pmid: 29519916
|
| [8] |
Zhao LJ, Lou HX, Peng Y, Chen SH, Fan L, Li XB. Elevated levels of circulating short-chain fatty acids and bile acids in type 2 diabetes are linked to gut barrier disruption and disordered gut microbiota. Diabetes Res Clin Pract, 2020, 169: 108418.
doi: 10.1016/j.diabres.2020.108418
|
| [9] |
Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol, 2020, 16(11): 642-653.
|
| [10] |
Amer DA. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care, 2018, 41(Suppl. 1): S73-S85.
doi: 10.2337/dc18-S008
|
), 汪锴(
